north american pharmaceutical revenue is an issuer-specific segment revenue measure for McKesson's North American Pharmaceutical business. McKesson reported fiscal 2026 North American Pharmaceutical revenue of $336.652 billion, up 11% from $304.507 billion. Management said the increase was driven primarily by higher U.S. pharmacy and healthcare-provider volumes, especially retail national accounts.
What moves it
Revenue growth can reflect transaction volume, pharmaceutical or product mix, customer additions, acquisitions, pricing, and the mix between product distribution and services. For North American Pharmaceutical, the underlying operating drivers should be read alongside the segment's profit and margin rather than treating revenue growth alone as value creation.
Investor read-through
McKesson's segment revenue is not a standardized industry KPI and does not imply equivalent economics across distributors or healthcare-service companies. Large pharmaceutical-distribution revenue bases can carry very different margins from technology or provider-service revenue, so compare the revenue measure with segment operating profit and segment operating margin.
Primary source: McKesson fiscal 2026 Form 10-K.
Part of the Healthcare Distribution & Services Economics
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
- MCKOpen operating-model research →15 of 15 reviewed concepts in Healthcare Distribution & Services EconomicsCore pharmaceutical distribution scale and margin4 of 4 bridge concepts supportedContinue through this bridge:Pharmaceutical Distribution MarginPharmaceutical Distribution Operating ProfitService Revenue Mix
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare healthcare distribution and services stocks
Continue into stock comparison after reviewing segment scale, profitability, service mix, and capital intensity across healthcare distribution and services businesses.
Explore more topics in the Financial Research Encyclopedia.